JakobDupontMDMA
Oncology • South San Francisco, CABreast Cancer, Gynecologic Cancer, Clinical Pharmacology
Global Head of Research and Development Atara Biotherapeutics
Dr. Dupont is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
611 Gateway Blvd
South San Francisco, CA 94080Phone+1 650-474-1188
Summary
- Dr. Jakob Dupont is an oncologist in Hillsborough, CA. He received his medical degree from Weill Cornell Medical College of Cornell University and has been in practice 21 years. He specializes in medical oncology, breast cancer, gynecologic cancer, early drug development, Immuno-Oncology, Allergy and Immunology and autoimmune disease.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 1999
University of MichiganInternship, Internal Medicine, 1996 - 1997
Weill Cornell MedicineClass of 1996
Certifications & Licensure
CA State Medical License 2008 - 2026
Clinical Trials
- VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma Start of enrollment: 2001 Nov 01
- VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma Start of enrollment: 2002 Apr 01
- Polyglutamate Camptothecin in Treating Patients With Advanced Cancer Start of enrollment: 2003 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 190 citationsTumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasXingxing Zang, Peggy S. Sullivan, Robert A. Soslow, Rebecca Waitz, Victor E. Reuter
Modern Pathology. 2010-08-01 - 131 citationsA First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.Antonio Jimeno, Michael S. Gordon, Rashmi Chugh, Wells A. Messersmith, David S. Mendelson
Clinical Cancer Research. 2017-12-15 - 182 citationsPhase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid TumorsA. Craig Lockhart, Mace L. Rothenberg, Jakob Dupont, Wendy A Cooper, Paul Chevalier
Journal of Clinical Oncology. 2010-01-10
Press Mentions
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2022 Earnings Call TranscriptDecember 30th, 2022- Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MSJuly 12th, 2022
- Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-Cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-Cel EMA Regulatory ProgressJune 4th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
Industry Relationships
- Chief Medical Officer, OncoMed Pharmaceuticals Inc
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
